

LISTING OF CLAIMS:

Claim 1. (original): A method for the detection of a pathogenic form of a prion protein in a sample, comprising providing a container, pretreating the container to deposit on a surface of the container a coating of a cellulose derivative capable of favoring the binding of pathogenic prion protein to said container surface over the binding of cellular prion protein, incubating the sample in said container to bind any pathogenic prion protein present in the sample to said container surface, labelling the thus immobilized pathogenic prion protein, if present, with an appropriate labelling agent using an anti-prion antibody capable of binding to pathogenic prion protein and detecting the presence of labelling agent attached to the container surface.

Claim 2. (original): A method according to claim 1, which is an enzyme-linked immunosorbent assay (ELISA) using a labelling enzyme as labelling agent, wherein the presence of labelling enzyme attached to the container surface is detected by incubating the container with an appropriate substrate for the labelling enzyme and detecting conversion of the substrate into a coloured, fluorescent or luminescent product.

Claim 3. (currently amended): A method according to claim 1 ~~or 2~~, wherein the cellulose derivative used favors the binding of pathogenic prion protein over cellular prion protein by enhancing the binding of pathogenic prion protein to the container surface, or reducing the binding of cellular prion protein to the container surface, or both.

Claim 4. (currently amended): A method according to claim 1 ~~any one of claims 1-3~~, wherein the container is transparent.

Claim 5. (currently amended): A method according to claim 1 ~~any one of claims 1-4~~, wherein the container is a well of a microtitre plate.

Claim 6. (currently amended): A method according to claim 1 ~~any one of claims 1-5~~, wherein the coating of a cellulose derivative deposited on a surface of the container is transparent.

Claim 7. (currently amended): A method according to claim 1 ~~any one of claims 1-6~~, wherein the cellulose derivative used is insoluble in water.

Claim 8. (original): A method according to claim 7, wherein the cellulose derivative is a nitrocellulose.

Claim 9. (currently amended): A method according to claim 1 ~~any one of claims 1-8~~, wherein said pretreatment comprises incubating the container with a solution of an appropriate cellulose derivative in a non-aggressive solvent, such as methanol or ethanol, followed by evaporation of the solvent.

Claim 10. (original): A method according to claim 9, wherein the solution contains from 0.001 to 20 mg/ml of the cellulose derivative.

Claim 11. (currently amended): A method according to claim 1 ~~any one of claims 1-10~~, wherein the cellulose derivative is deposited onto the surface of the container in an amount of from 1 to 20,000 ng/mm².

Claim 12. (currently amended): A method according to claim 1 ~~any one of claims 1-11~~, wherein the sample is pretreated with an enzyme capable of digesting cellular prion protein.

Claim 13. (original): A method according to claim 12, wherein the enzyme is proteinase K.

Claim 14. (currently amended): A method according to claim 12 ~~or 13~~, wherein the enzymatic digestion is stopped by briefly heating the sample to a temperature of from 70 to 100 °C to inactivate the enzyme.

Claim 15. (original): A method according to claim 14, wherein the sample after the inactivation of the enzyme is treated with detergent at a temperature of from 70 to 100 °C to denature the protein in the sample.

Claim 16. (currently amended): A method according to claim 12 ~~any one of claims 12-15~~, wherein the pretreatment of the container with a cellulose derivative favors the binding of enzymatically pretreated pathogenic prion protein over enzymatically pretreated cellular prion protein by enhancing the binding of enzymatically pretreated pathogenic prion protein to the container surface, or reducing the binding of enzymatically pretreated cellular prion protein to the container surface, or both.

Claim 17. (currently amended): A method according to claim 1 ~~any one of claims 1-16~~, wherein the labelling of any pathogenic prion protein immobilized onto the container surface is performed either directly with an enzyme-labelled anti-prion antibody, or indirectly with a non-labelled anti-prion antibody followed by an enzyme-labelled antibody capable of binding to the anti-prion antibody.

Claim 18. (currently amended): A method according to claim 1 ~~any one of claims 1-17~~, wherein a peroxidase, such as Horse Radish Peroxidase, is used as a labelling enzyme.

Claim 19. (currently amended): A method according to claim 1 ~~any one of claims 1-18~~, wherein 3,3',5,5'-tetra-methylbenzidine is used as a substrate for the labelling enzyme.

Claim 20. (currently amended): A method according to claim 1 ~~any one of claims 1-19~~, wherein the substrate conversion results in a coloured material which is detected by direct readout of the absorbance.

Claim 21. (currently amended): A method according to claim 1 ~~any one of claims 1-20~~, wherein the quantitative occurrence of a pathogenic form of a prion protein in a sample is determined.

Claim 22. A method according to claim 1 ~~any one of claims 1-21~~, wherein the ELISA includes a parallel ELISA without pretreatment of the container as a control of complete enzymatic digestion of cellular prion protein.

Claim 23. (currently amended): A method according to claim 1 ~~any one of claims 1-22~~, wherein the sample is derived from brain or lymphoid tissue of a human or animal.

Claim 24. (currently amended): A method according to claim 1 ~~any one of claims 1-22~~, wherein the sample is a body fluid, such as blood, plasma, cerebrospinal fluid, saliva, sputum, seminal fluid, vaginal fluid or urine.

Claim 25. (original): A method for separating pathogenic prion protein from a mixture which contains pathogenic prion protein and cellular prion protein comprising contacting the mixture with a surface which preferentially binds pathogenic prion protein and separating the non-bound material from said surface.

Claim 26. (original): A method according to claim 25, wherein said surface is made of, or coated with, a water-insoluble cellulose derivative, such as nitrocellulose.

Claim 27. (currently amended): A method according to claim 25 ~~or 26~~, wherein said surface is a surface of a microtitre plate well coated with a layer of nitrocellulose.

Claim 28. (currently amended): A method according to claim 25 ~~or 26~~, wherein said surface is a surface of a bead or column filling which is made of, or coated with, nitrocellulose.

Claim 29. (currently amended): A method according to claim 25 ~~any one of claims 25-28~~, wherein said mixture is pretreated with an enzyme capable of digesting cellular prion protein, such as proteinase K.

Claim 30. (original): A method according to claim 29, wherein after the enzymatic digestion first the digestion enzyme is inactivated and then the protein which is present in the mixture is denatured.